Literature DB >> 20376613

Adenovirus.

Jason G Smith1, Christopher M Wiethoff, Phoebe L Stewart, Glen R Nemerow.   

Abstract

Of the 53 different human adenovirus (HAdV) serotypes belonging to species A-G, a significant number are associated with acute respiratory, gastrointestinal and ocular infections. Replication-defective HAdV-5-based vectors also continue to play a significant role in gene transfer trials and in vaccine delivery efforts in the clinic. Although significant progress has been made from studies of AdV biology, we still have an incomplete understanding of AdV's structure as well as its multifactorial interactions with the host. Continuing efforts to improve knowledge in these areas, as discussed in this chapter, will be crucial for revealing the mechanisms of AdV pathogenesis and for allowing optimal use of AdV vectors for biomedical applications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20376613      PMCID: PMC3093298          DOI: 10.1007/82_2010_16

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  168 in total

1.  Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein.

Authors:  N Miyazawa; R G Crystal; P L Leopold
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 2.  Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee.

Authors: 
Journal:  Hum Gene Ther       Date:  2002-01-01       Impact factor: 5.695

3.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Antipeptide antisera define neutralizing epitopes on the adenovirus hexon.

Authors:  C I Toogood; J Crompton; R T Hay
Journal:  J Gen Virol       Date:  1992-06       Impact factor: 3.891

5.  Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber.

Authors:  V Legrand; D Spehner; Y Schlesinger; N Settelen; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Mechanism of adenovirus improvement of cationic liposome-mediated gene transfer.

Authors:  C Meunier-Durmort; R Picart; T Ragot; M Perricaudet; B Hainque; C Forest
Journal:  Biochim Biophys Acta       Date:  1997-11-13

7.  Proteins are cointernalized with virion particles during early infection.

Authors:  M J Otero; L Carrasco
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

8.  Infection with replication-deficient adenovirus induces changes in the dynamic instability of host cell microtubules.

Authors:  James C Warren; Adam Rutkowski; Lynne Cassimeris
Journal:  Mol Biol Cell       Date:  2006-06-14       Impact factor: 4.138

9.  Glycocalyx restricts adenoviral vector access to apical receptors expressed on respiratory epithelium in vitro and in vivo: role for tethered mucins as barriers to lumenal infection.

Authors:  Jaclyn R Stonebraker; Danielle Wagner; Robert W Lefensty; Kimberlie Burns; Sandra J Gendler; Jeffrey M Bergelson; Richard C Boucher; Wanda K O'Neal; Raymond J Pickles
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Infectious entry pathway of adenovirus type 2.

Authors:  M J Varga; C Weibull; E Everitt
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

View more
  49 in total

1.  Functional genetic and biophysical analyses of membrane disruption by human adenovirus.

Authors:  Crystal L Moyer; Christopher M Wiethoff; Oana Maier; Jason G Smith; Glen R Nemerow
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Genomic stability of adipogenic human adenovirus 36.

Authors:  J-H Nam; H-N Na; R L Atkinson; N V Dhurandhar
Journal:  Int J Obes (Lond)       Date:  2013-05-06       Impact factor: 5.095

Review 4.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  The effect of fiber truncations on the stability of adenovirus type 5.

Authors:  Grit Kupgan; Danielle C Hentges; Nathan J Muschinske; William D Picking; Wendy L Picking; Joshua D Ramsey
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

6.  Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment.

Authors:  Julian Scherer; Richard B Vallee
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

7.  The role of capsid maturation on adenovirus priming for sequential uncoating.

Authors:  Ana J Pérez-Berná; Alvaro Ortega-Esteban; Rosa Menéndez-Conejero; Dennis C Winkler; Margarita Menéndez; Alasdair C Steven; S Jane Flint; Pedro J de Pablo; Carmen San Martín
Journal:  J Biol Chem       Date:  2012-07-12       Impact factor: 5.157

8.  Production and purification of non replicative canine adenovirus type 2 derived vectors.

Authors:  Marion Szelechowski; Corinne Bergeron; Daniel Gonzalez-Dunia; Bernard Klonjkowski
Journal:  J Vis Exp       Date:  2013-12-03       Impact factor: 1.355

9.  Reduced infectivity of adenovirus type 5 particles and degradation of entering viral genomes associated with incomplete processing of the preterminal protein.

Authors:  Sayuri E Kato; Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Mechanisms of human adenovirus inactivation by sunlight and UVC light as examined by quantitative PCR and quantitative proteomics.

Authors:  Franziska Bosshard; Florence Armand; Romain Hamelin; Tamar Kohn
Journal:  Appl Environ Microbiol       Date:  2012-12-14       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.